Treatment of malignant hypercalcaemia with clodronate.

We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppre...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Percival, R. C., Paterson, A. D., Yates, A. J., Beard, D. J., Douglas, D. L., Neal, F. E., Russell, R. G., Kanis, J. A.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1985
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977044/
https://ncbi.nlm.nih.gov/pubmed/3158326
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki